A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician?s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia.
A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia, Intermediate or Higher-Risk Myelodysplastic Syndromes, bcr-abl negative Myeloproliferative, Myelodysplastic/Myeloproliferative Neoplasms and Multiple Myeloma
BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease
in Acute Myeloid Leukemia 2 BLAST MRD AML-2: A randomized Phase 2 Study of the
Venetoclax, Azacitidine, and Pembrolizumab VAP Versus Venetoclax and Azacitidine as First
Line Therapy in Older Patients with Acute Myeloid Leukemia AML who are Ineligible or who
Refuse Intensive Chemotherapy
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive Ph+ Acute Lymphoblastic Leukemia ALL Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Phase III, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus
Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients
With Newly Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia
Ph+ ALL
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor MUD versus HLA-Haploidentical Related Haplo Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults AYA with Acute Leukemia or Myelodysplastic Syndrome MDS
A Phase I Study of DS-3032B in Combination with Quizartinib in Subjects with FLT3-ITD Mutant Acute Myeloid Leukemia That are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
Phase I study of venetoclax/azacitidine or venetoclax in combination with ziftomenib KO-539 or standard induction cytarabine/daunorubicin 7+3 chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia